Advertisement

Neuroscience and Behavioral Physiology

, Volume 49, Issue 1, pp 54–59 | Cite as

The Antioxidant, Anti-Inflammatory, and Sedative Effects of Melatonin: Results of Clinical Trials

  • D. I. Burchakov
  • Yu. B. Uspenskaya
Article
  • 6 Downloads

We present published data (clinical trials and systematic reviews) of the antioxidant and anti-inflammatory effects of melatonin. The results of studies published in recent years on these effects in humans and animals are summarized. Melatonin has been shown to protect the cardiovascular system from damage induced by ischemia/reperfusion when given promptly; it has a neuroprotective effect in neonates after asphyxia; it is an effective agent in the complex treatment of irritable bowel syndrome and inflammatory gut disorders (Crohn’s disease and ulcerative colitis). It is also regarded as a premedication agent, decreasing anxiety for surgery, potentially allowing prescription of benzodiazepines to be avoided.

Keywords

melatonin ischemia/reperfusion premedication gut diseases 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    A. Anighoro, J. Bajorath, and G. Rastelli, “Polypharmacology: Challenges and opportunities in drug discovery,” J. Med. Chem., 57, 7874–7887 (2014),  https://doi.org/10.1021/jm5006463.CrossRefGoogle Scholar
  2. 2.
    R. J. Reiter, J. C. Mayo, D. X. Tan, R. M. Sainz, M. Alatorre-Jimenez, and L. Qin, “Melatonin as an antioxidant: under promises but overdelivers,” J. Pineal Res., 61, 253–278 (2016),  https://doi.org/10.1111/jpi.12360.CrossRefGoogle Scholar
  3. 3.
    D. L. Carden, and D. N. Granger, “Pathophysiology of ischaemiareperfusion injury,” J. Pathol., 190, 255–266 (2000),  https://doi.org/10.1002/(SICI)1096-9896(200002)190:3.CrossRefGoogle Scholar
  4. 4.
    K. H. Dwaich, F. G. Y. Al-Amran, B. I. M. Al-Sheibani, and H. A. Al-Aubaidy, “Melatonin effects on myocardial ischemia-reperfusion injury: Impact on the outcome in patients undergoing coronary artery bypass grafting surgery,” Int. J. Cardiol., 221, 977–986 (2016),  https://doi.org/10.1016/j.ijcard.2016.07.108.CrossRefGoogle Scholar
  5. 5.
    A. E. Denktas, H. V. Anderson, J. McCarthy, and R. W. Smalling, “Total ischemic time,” JACC Cardiovasc. Interv., 4, 599–604 (2011),  https://doi.org/10.1016/j.jcin.2011.02.012.CrossRefGoogle Scholar
  6. 6.
    I. Gogenur, B. Kucukakin, L. Panduro Jensen, R. J. Reiter, and J. Rosenberg, “Melatonin reduces cardiac morbidity and markers of myocardial ischemia after elective abdominal aortic aneurism repair: a randomized, placebo-controlled, clinical trial,” J. Pineal Res., 57, 10–15 (2014),  https://doi.org/10.1111/jpi.12138.CrossRefGoogle Scholar
  7. 7.
    M. G. Poluektov, and S. L. Tsenteradze, “Potential for the use of melatonin in ischemic stroke,” Farmateka, 7, 31–35 (2013).Google Scholar
  8. 8.
    E. Ramos, P. Patino, R. J. Reiter, E. Gil-Martin, J. Marco-Contelles, E. Parada, C. Rios, A. Romero, and J. Egea, “Ischemic brain injury: New insights on the protective role of melatonin,” Free Radic. Biol. Med., 104, 32–53 (2017), https://doi.org/ https://doi.org/10.1016/j.freeradbiomed.2017.01.005.
  9. 9.
    Ya. Levin, “Melatonin and vascular brain disease,” Russ. Med. Zh., 26, 1732 (2008).Google Scholar
  10. 10.
    F. Fulia, E. Gitto, S. Cuzzocrea, R. J. Reiter, L. Dugo, P. Gitto, S. Barberi, S. Cordaro, and I. Barberi, “Increased levels of malondialdehyde and nitrite/nitrate in the blood of asphyxiated newborns: reduction by melatonin,” J. Pineal Res., 31, 343–349 (2001),  https://doi.org/10.1034/j.1600-079X.2001.310409.x.CrossRefGoogle Scholar
  11. 11.
    H. Aly, H. Elmahdy, M. El-Dib, M. Rowisha, M. Awny, T. El- Gohary, M. Elbatch, M. Hamisa, and A. R. El-Mashad, “Melatonin use for neuroprotection in perinatal asphyxia: a randomized controlled pilot study,” J. Perinatol., 35, 186–191 (2015),  https://doi.org/10.1038/jp.2014.186.CrossRefGoogle Scholar
  12. 12.
    P. J. Parekh, E. C. Oldfield Iv, V. Challapalli, J. C. Ware, and D. A. Johnson, “Sleep disorders and inflammatory disease activity: chicken or the egg?” Am. J. Gastroenterol., 110, 484–488 (2015),  https://doi.org/10.1038/ajg.2014.247.CrossRefGoogle Scholar
  13. 13.
    A. Hungin, P. Whorwell, J. Tack, and F. Mearin, “The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects,” Aliment. Pharmacol. Ther., 17, 643–650 (2003),  https://doi.org/10.1046/j.0269-2813.2003.01456.x.CrossRefGoogle Scholar
  14. 14.
    R. Fass, S. Fullerton, S. Tung, and E. A. Mayer, “Sleep disturbances in clinic patients with functional bowel disorders,” Am. J. Gastroenterol., 95, 1195–2000 (2000),  https://doi.org/10.1111/j.1572-0241.2000.02009.x.CrossRefGoogle Scholar
  15. 15.
    M. M. Heitkemper, C. J. Han, M. E. Jarrett, H. Gu, D. Djukovic, R. J. Shulman, D. Raftery, W. A. Henderson, and K. C. Cain, “Serum tryptophan metabolite levels during sleep in patients with and without irritable bowel syndrome (IBS),” Biol. Res. Nurs., 18, 193–198 (2016),  https://doi.org/10.1177/1099800415594251.CrossRefGoogle Scholar
  16. 16.
    M. Storr, P. Koppitz, A. Sibaev, D. Saur, M. Kurjak, H. Franck, V. Schusdziarra, and H. D. Allescher, “Melatonin reduces non-adrenergic, non-cholinergic relaxant neurotransmission by inhibition of nitric oxide synthase activity in the gastrointestinal tract of rodents in vitro,” J. Pineal Res., 33, 101–108 (2002),  https://doi.org/10.1034/j.1600-079X.2002.02909.x.CrossRefGoogle Scholar
  17. 17.
    W. Lu, K. Gwee, S. Moochhalla, and K. Ho, “Melatonin improves bowel symptoms in female patients with irritable bowel syndrome: a double-blind placebo-controlled study,” Aliment. Pharmacol. Ther., 22, 927–934 (2005),  https://doi.org/10.1111/j.1365-2036.2005.02673.x.CrossRefGoogle Scholar
  18. 18.
    T. Ali, M. F. Madhoun, W. C. Orr, and D. T. Rubin, “Assessment of the relationship between quality of sleep and disease activity in inflammatory bowel disease patients,” Inflamm. Bowel Dis., 19, 2440–2443 (2013),  https://doi.org/10.1097/MIB.0b013e3182a0ea54.CrossRefGoogle Scholar
  19. 19.
    A. N. Ananthakrishnan, M. D. Long, C. F. Martin, R. S. Sandler, and M. D. Kappelman, “Sleep disturbance and risk of active disease in patients with Crohn’s disease and ulcerative colitis,” Clin. Gastro-enterol. Hepatol., 11, 965–971 (2013),  https://doi.org/10.1016/j.cgh.2013.01.021.CrossRefGoogle Scholar
  20. 20.
    P. Boznańska, P. Wichan, A. Stepień, M. Wiśniewska-Jarosńska, J. Smigielski, K. Szadkowski, and K. Stec-Michalska, “24-hour urinary 6-hydroxymelatonin sulfate excretion in patients with ulcerative colitis,” Pol. Merkur. Lek., 22, 369–372 (2007).Google Scholar
  21. 21.
    C. Chojnacki, M. Wisniewska-Jarosinska, E. Walecka-Kapica, G. Klupinska, J. Jaworek, and J. Chojnacki, “Evaluation of melatonin effectiveness in the adjuvant treatment of ulcerative colitis,” J. Physiol. Pharmacol., 62, 327–334 (2011).PubMedGoogle Scholar
  22. 22.
    M. Rapoport (ed.), Melatonin: Perspectives for Clinical Utilization, IMA-PRESS., Moscow (2012).Google Scholar
  23. 23.
    P. P. Trivedi, G. B. Jena, K. B. Tikoo, and V. Kumar, “Melatonin modulated autophagy and Nrf2 signaling pathways in mice with colitis-associated colon carcinogenesis,” Mol. Carcinog., 55, 255–267 (2016),  https://doi.org/10.1002/mc.22274.CrossRefGoogle Scholar
  24. 24.
    M. G. Poluektov, “Insomnia,” in: Somnology and Sleep Medicine, M. G. Poluektov (ed.) Medforum, Moscow (2016).Google Scholar
  25. 25.
    C. Garzon, J. M. Guerrero, O. Aramburu, and T. Guzman, “Effect of melatonin administration on sleep, behavioral disorders and hypnotic drug discontinuation in the elderly: a randomized, double-blind, placebo-controlled study,” Aging Clin. Exp. Res., 21, 38–42 (2009),  https://doi.org/10.1007/BF03324897.CrossRefGoogle Scholar
  26. 26.
    F. J. H. A. Vissers, P. G. Knipschild, and H. F. J. M. Crebolder, “Is melatonin helpful in stopping the long-term use of hypnotics? A discontinuation trial,” Pharm. World Sci., 29, 641–646 (2007),  https://doi.org/10.1007/s11096-007-9118-y.CrossRefGoogle Scholar
  27. 27.
    A. Wright, J. Diebold, J. Otal, C. Stoneman, J. Wong, C. Wallace, and M. Duffett, “The effect of melatonin on benzodiazepine discontinuation and sleep quality in adults attempting to discontinue benzodiazepines: A systematic review and meta-analysis,” Drugs Aging, 32, 1009–1018 (2015),  https://doi.org/10.1007/s40266-015-0322-5.CrossRefGoogle Scholar
  28. 28.
    G. H. Guyatt, A. D. Oxman, G. E. Vist, R. Kunz, Y. Falck-Ytter, P. Alonso-Coello, and H. J. Schunemann, “GRADE: An emerging consensus on rating quality of evidence and strength of recommendations,” Chin. J. Evidence-Based Med., 9, 8–11 (2009), https://doi.org/ https://doi.org/10.1136/bmj.39489.470347.AD.
  29. 29.
    D. Ionescu, C. Badescu, A. Ilie, I. Miclutia, C. Iancu, D. Ion, H. Vasian, C. Bondor, I. Acalovschi, and T. Mocan, “Melatonin as premedication for laparoscopic cholecystectomy: a double-blind, placebocontrolled study,” South African J. Anaesth. Analg., 14, 8–11 (2008),  https://doi.org/10.1080/22201173.2008.10872555.Google Scholar
  30. 30.
    M. Karasek, and K. Winczyk, “Melatonin in humans,” J. Physiol. Pharmacol., 57, 19–39 (2006), https://doi.org/https://doi.org/10.1056/NEJM19970 1163360306.Google Scholar
  31. 31.
    M. V. Hansen, N. L. Halladin, J. Rosenberg, et al., “Melatonin for pre- and postoperative anxiety in adults,” Cochrane Libr. (2015),  https://doi.org/10.1002/14651858.CD009861.pub2.Copyright.
  32. 32.
    J. B. Gross, J. L. Apfelbaum, R. A. Caplan, R. T. Connis, C. J. Cote, D. G. Nickinovich, D. S. Ward, E. M. Weawer, and L. Ydens, “Practice guidelines for the perioperative management of patients with obstructive sleep apnea,” Anesthesiology, 120, 268–286 (2014),  https://doi.org/10.1097/ALN.0000000000000053.CrossRefGoogle Scholar
  33. 33.
    L. Pulak and L. Jensen, “Sleep in the intensive care unit: A review,” J. Intensive Care Med., 31, 14–23 (2016),  https://doi.org/10.1016/j.ncl.2011.08.004.CrossRefGoogle Scholar
  34. 34.
    J. Karkela, O. Vakkuri, S. Kaukinen, W. Huang, and M. Pasanen, “The influence of anaesthesia and surgery on the circadian rhythm of melatonin,” Acta Anaesthesiol. Scand., 46, 30–36 (2002), https://doi.org/  https://doi.org/10.1034/j.1399-6576.2002.460106.x.CrossRefPubMedGoogle Scholar
  35. 35.
    S. R. Lewis, P. Alderson, and A. F. Smith, “Melatonin for the promotion of sleep in the intensive care unit (Protocol),” Cochrane Database Syst. Rev. (2016),  https://doi.org/10.1002/14651858.CD012454.
  36. 36.
    J. T. Sharkey, R. Puttaramu, R. A. Word, and J. Olcese, “Melatonin synergizes with oxytocin to enhance contractility of human myometrial smooth muscle cells,” J. Clin. Endocrinol. Metab., 94, 421–427 (2009),  https://doi.org/10.1210/jc.2008-1723.CrossRefGoogle Scholar
  37. 37.
    L. Marseglia, G. D’Angelo, S. Manti, R. J. Reiter, and E. Gitto, “Potential utility of melatonin in preeclampsia, intrauterine fetal growth retardation, and perinatal asphyxia,” Reprod. Sci., 23, 970–977 (2016),  https://doi.org/10.1177/1933719115612132.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Sechenov First Moscow State Medical University (Sechenov University)MoscowRussia

Personalised recommendations